Yissum - Research Development Company of the Hebrew University

pH-Based Sustained-Release Drug Delivery Coating for Medical Devices

Posted by Yissum - Research Development Company of the Hebrew UniversityResponsive · Innovative Products and Technologies · Israel

Summary of the technology

Cluster9
sustained-release drug delivery system that can be applied directly to an inserted catheter, teeth, skin and other surfaces. Drug release is controlled by the pH of surroundings. A “built–in” pH sensor controls the release rate. For example, the release rate can be increased in acid conditions.

Project ID : 8-2011-2599

Yissum - Research Development Company of the Hebrew University

Description of the technology

Enables in situ delivery of active ingredients where and when required

Categories

Veterinary Medicine /Animal Science , Human Medicine, Life Science & Biotechnology, Veterinary Formulations, Medical device, Dental

Development Stage

Developed as varnish tested on animal teeth; tests of varnish on catheters tested in vitro and in vivo on dogs and rats; ongoing research

Patent Status

Patent pending in US and Europe

Highlights

  • Many kinds of surfaces are notorious sources of infection. Eradication of bacteria immobilized as biofilms on these surfaces is a major biological problem.
  • Prevention of the development of biofilms is of prime concern to veterinarians, medical professionals, dentists and others.
  • Urinary tract catheters, dental surfaces, stents, implants, and indwelling devices are all prone to accumulation of biofilms.
  • Sustained-release, localised drug delivery is a novel method for eradicating these biofilms.

Our Innovation

A sustained-release drug delivery system that can be applied directly to an inserted catheter, teeth, skin and other surfaces. Drug release is controlled by the pH of surroundings. A “built–in” pH sensor controls the release rate. For example, the release rate can be increased in acid conditions.

Figures: Comparison of urinary catheters under confocal microscope. The light intensity is significantly lower in the catheter coated with sustained-release antiseptic varnish (treated) when compared with the untreated catheter

Key Features

  • This unique technology controls the release of the drug, overcoming the disadvantages of other delivery methods in affecting diseases.
  • Controlled duration and concentrations of a drug in the target site enables reduced amount of applied drug, minimizes side effects (such as the recurrence of oral infections, the development of resistant bacterial strains, bitter taste, tooth staining etc. and).
  • The technology is a pharmaceutical platform that can incorporate many types of drugs (antibacterial, anti inflammatory, anti cancer etc.)
  • The technology has been tested in vitro, ex vivo, in animals, and in humans.
  • The technology can be applied as varnishes, gels, foams and spray.
  • The system has been developed as a varnish that provides sustained release of active ingredients when applied to catheters, teeth, skin, stents, implants, udders of cows, and more.
  • Leads to reduction of infections, better clinical improvement, and better patient compliance.

Development Milestones

  • Seeking funding and industrial cooperation to develop applications for veterinary, medical, and dental use.

The Opportunity

  • Catheters, stents, and orthopaedic implants are frequently involved in infections caused by the development of biofilms
  • Appropriate for veterinary as well as human applications
  • Biofilm formation associated with oral disorders such as hypersensitive teeth, tooth staining and oral ulceration.

Project manager

Mel Larrosa
VP Business Development Healthcare

Project researchers

Doron Steinberg
HUJI, Faculty of Dental Medicine
Institute of Dental Sciences

Eran Lavy
HUJI, Faculty of Agricultural, Food and Environmental Quality Sciences
The Koret School of Veterinary Medicine

Michael Friedman
HUJI, School of Medicine - IMRIC
School of Pharmacy- Institute for Drug Research

Related keywords

  • Medicine, Human Health
  • Biology / Biotechnology
  • Genome Research
  • Micro- and Nanotechnology related to Biological sciences
  • Veterinary Medicine
  • Recombinant DNA
  • Monoclonal Antibodies and Hybridomas
  • Gene Splicing and Manufacturing Equipment
  • Other Genetic Engineering
  • Molecular design Market
  • Microbiology Market
  • Micro- and Nanotechnology related to Biological sciences
  • Biochemistry / Biophysics Market
  • Toxicology Market
  • In vitro Testing, Trials Market
  • Stem cells and biobanks
  • Cellular and Molecular Biology Market
  • Population genetics Market
  • Gene Expression, Proteom Research Market
  • Bioinformatics Market
  • Enzymology/Protein Engineering/Fermentation
  • Genetic Engineering Market
  • Clinical Medicine
  • Anatomy, Pathology, Immunology, Physiology
  • Agro and Marine biotech
  • Other Medical/Health Related
  • Therapeutic
  • Diagnostic
  • Animal health
  • Life Science & Biotechnology
  • medical device

About Yissum - Research Development Company of the Hebrew University

Technology Transfer Office from Israel

Yissum Research Development Company of the Hebrew University of Jerusalem Ltd. Founded in 1964 to protect and commercialize the Hebrew University’s intellectual property. Ranked among the top technology transfer companies, Yissum has registered over 8,900 patents covering 2,500 inventions; has licensed out 800 technologies and has spun-off 90 companies. Products that are based on Hebrew University technologies and were commercialized by Yissum generate today over $2 Billion in annual sales.

Send your request

By clicking "Send your request" you are signing up and accepting our Terms of Service and Privacy policy

Technology Offers on Innoget are directly posted and managed by its members as well as evaluation of requests for information. Innoget is the trusted open innovation and science network aimed at directly connect industry needs with professionals online.